Thesis (Ph. D.)--University of Texas at Austin, 1998. / Vita. Includes bibliographical references (leaves 113-128). Available also in a digital version from Dissertation Abstracts.

Thesis (M.S.W.)--Smith College School for Social Work, Northampton, Mass., 2009. / Includes bibliographical references (p. 94-100).

Thesis (Ph. D.)--University of Michigan, 1979. / Includes bibliographical references (leaves 298-309).

Thesis (M.S.)--University of Michigan, 1985.

Thesis (Ph. D.)--Michigan State University, 2004. / Includes bibliographical references (leaves 191-200). Also available online (PDF file) by a subscription to the set or by purchasing the individual file.

Thesis (M.S.)--University of Wisconsin--Madison, 1974. / eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references.

Thesis (M.Soc.Sc.)--University of Hong Kong, 1991. / Also available in print.

Thesis (Ph. D.)--Michigan State University, 2004. / Includes bibliographical references (leaves 191-200).

abstract: The following study evaluated the effectiveness of a self-monitoring strategy on independent work behavior. The three subjects were in first grade, seven years old, identified with mild mental retardation (MIMR), and had an Individualized Education Plan (IEP) with targeted functional academic and behavior goals. The purpose of this study was to investigate the effect of a self-monitoring strategy on on-task independent work behavior and task completion. The research sought to determine whether or not a self-monitoring strategy would affect on-task independent work behavior and task completion. A multiple baseline across subjects design was used. Data were collected using a frequency count of off-task behavior. The self-monitoring strategy was found to be successful with all three subjects in the study. Overall, the subjects demonstrated a decrease in off-task behavior during independent work time after the intervention was introduced. / Dissertation/Thesis / M.A. Special Education 2010

O artigo apresenta um ensaio clínico cujo objetivo foi avaliar a eficácia e tolerabilidade, a curto prazo, da Risperidona e do Metilfenidato na redução de sintomas do Transtorno de Déficit de Atenção/Hiperatividade (TDAH) em crianças e adolescentes com Retardo Mental Moderado (RMM) que preencheram os critérios do DSM-IV para TDAH. Foram acompanhados, durante 4 semanas, 46 pacientes com diagnóstico de RMM e TDAH que receberam metilfenidato ou risperidona. As medidas de eficácia foram avaliadas através da aplicação das escalas “Swanson, Nolan, and Pelham” – SNAP-IV e do Formulário Nisonger Para Avaliação do Comportamento da Criança. Os efeitos colaterais das medicações foram detectados através da aplicação das escalas “Barkley’s Side-Effects Rating Scale” (SERS) e da “Ugvald for Kliniske Undersgelser”(UKU). Não foram detectadas diferenças significativas entre os dois grupos no final do ensaio (todos os TE ≤ 0.27). Ocorreu uma significativa redução de peso nos pacientes do grupo do metilfenidato e um significativo ganho de peso nos pacientes do grupo da risperidona. Nossos achados preliminares sugerem que tanto a risperidona como o metilfenidato podem ser eficazes na redução de sintomas do TDAH nestes pacientes com Retardo Mental Moderado. O perfil dos efeitos colaterais pode ser importante na decisão da medicação a ser escolhida. / The article describes a clinical trial. The objective was to evaluate the short-term efficacy and tolerability of risperidone and methylphenidate (MPH) in reducing symptoms related to attention-deficit/hyperactivity disorder (ADHD) in children and adolescents with Moderate Mental Retardation (MMR) who fulfilled DSM-IV criteria for ADHD. In a 4-week, 46 subjects with MMR and ADHD were enrolled and randomized for Risperidone or Methylphenidate (MPH). The outcome measurements for efficacy were the Swanson, Nolan, and Pelham Scale (SNAPIV), and the Nisonger Child Behavior Rating Form (NCBRF). Side effects were assessed by Barkley’s Side-Effects Rating Scale and Ugvald for Kliniske Undersgelser (UKU). There were no significant differences between the two groups in any scale at end of the trial (all ES ≤ 0.27). There was a significant weight reduction in MPH patients and a significant weight gain in the risperidone group. Our preliminary findings suggest that both risperidone and MPH might be effective in reducing ADHD symptoms in patients with moderate mental retardation. The profile of side effects might be of some importance in deciding which medication should be chosen.